- Home
- PRG vs VRDN Comparison
PRG vs VRDN Comparison
Compare PRG & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRG
- VRDN
- Stock Information
- Founded
- PRG 2020
- VRDN 2006
- Country
- PRG United States
- VRDN United States
- Employees
- PRG N/A
- VRDN N/A
- Industry
- PRG Diversified Commercial Services
- VRDN Medical Specialities
- Sector
- PRG Consumer Discretionary
- VRDN Health Care
- Exchange
- PRG Nasdaq
- VRDN Nasdaq
- Market Cap
- PRG 1.4B
- VRDN 1.5B
- IPO Year
- PRG N/A
- VRDN N/A
- Fundamental
- Price
- PRG $35.35
- VRDN $18.72
- Analyst Decision
- PRG Hold
- VRDN Strong Buy
- Analyst Count
- PRG 5
- VRDN 11
- Target Price
- PRG $37.20
- VRDN $38.80
- AVG Volume (30 Days)
- PRG 323.9K
- VRDN 870.3K
- Earning Date
- PRG 10-22-2025
- VRDN 08-06-2025
- Dividend Yield
- PRG 1.47%
- VRDN N/A
- EPS Growth
- PRG 109.72
- VRDN N/A
- EPS
- PRG 5.11
- VRDN N/A
- Revenue
- PRG $2,518,216,000.00
- VRDN $305,000.00
- Revenue This Year
- PRG $1.44
- VRDN N/A
- Revenue Next Year
- PRG $3.56
- VRDN $35,092.81
- P/E Ratio
- PRG $6.91
- VRDN N/A
- Revenue Growth
- PRG 5.17
- VRDN 5.90
- 52 Week Low
- PRG $23.50
- VRDN $9.90
- 52 Week High
- PRG $50.28
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- PRG 66.25
- VRDN 55.80
- Support Level
- PRG $34.44
- VRDN $18.12
- Resistance Level
- PRG $35.47
- VRDN $20.05
- Average True Range (ATR)
- PRG 0.84
- VRDN 1.02
- MACD
- PRG 0.03
- VRDN -0.02
- Stochastic Oscillator
- PRG 79.64
- VRDN 55.81
About PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).